AnalystBook Research · Company Intelligence

ASPEN AEROGELS INC

ASPNNYSE

Built from ASPEN AEROGELS INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Aspen Aerogels revenue fell 40.1% to $271.1M and swung to a large net loss, though FCF improved to -$4.6M.

The read at a glance✓ Audited against SEC data
  • Business mixAerogel insulation and thermal barriersNote
  • RevenueRevenue fell 40.1%Watch
  • ProfitabilityNet loss was $389.6MWatch
  • CashFCF improved to -$4.6MNote
  • Balance sheetEquity fell 61.7%Watch
  • Insiders0 buys / 3 sellsWatch
  • AccountingAltman-Z distress; EQ safeWatch

Business

Aspen Aerogels sells aerogel insulation and thermal barrier products through Thermal Barrier and Energy Industrial segments.

Where the revenue comes from

Fiscal 2025, as ASPEN AEROGELS INC reports it. History and quarterly detail are in the app.

  • Thermal Barrier$168.9M
  • Energy Industrial$102.2M

Leadership changes

From ASPEN AEROGELS INC's own filings, the day they're filed.

  • Cari Robinson · director · appointmenteff. 2024-08-14
  • Santhosh Daniel · Chief Accounting Officer · appointmenteff. 2023-09-13
  • Qualifying Termination · departure

Latest filings

  • 10-Q · Quarterly report2026-08-07
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-05-18
  • 10-Q · Quarterly report2026-05-08
  • 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ASPEN AEROGELS INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.